Literature DB >> 31780851

Arvinas's PROTACs pass first safety and PK analysis.

Asher Mullard.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31780851     DOI： 10.1038/d41573-019-00188-4

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

1.  Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.

Authors:  Xin Han; Lijie Zhao; Weiguo Xiang; Chong Qin; Bukeyan Miao; Donna McEachern; Yu Wang; Hoda Metwally; Lu Wang; Aleksas Matvekas; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2021-08-25       Impact factor: 7.446

Review 2.  Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras.

Authors:  Chunlong Zhao; Frank J Dekker
Journal:  ACS Pharmacol Transl Sci       Date:  2022-08-22

Review 3.  Major Advances in Emerging Degrader Technologies.

Authors:  Hang Luo; Li Wu; Yujian He; Chong Qin; Xinjing Tang
Journal:  Front Cell Dev Biol       Date:  2022-06-22

Review 4.  Avoid the trap: Targeting PARP1 beyond human malignancy.

Authors:  Chiho Kim; Chuo Chen; Yonghao Yu
Journal:  Cell Chem Biol       Date:  2021-03-02       Impact factor: 8.116

Review 5.  The Roles of Post-Translational Modifications on mTOR Signaling.

Authors:  Shasha Yin; Liu Liu; Wenjian Gan
Journal:  Int J Mol Sci       Date:  2021-02-11       Impact factor: 5.923

6.  Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity.

Authors:  Victoria G Klein; Adam G Bond; Conner Craigon; R Scott Lokey; Alessio Ciulli
Journal:  J Med Chem       Date:  2021-12-09       Impact factor: 7.446

Review 7.  Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?

Authors:  Ludovica Lospinoso Severini; Francesca Bufalieri; Paola Infante; Lucia Di Marcotullio
Journal:  Front Cell Dev Biol       Date:  2022-02-15

8.  Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.

Authors:  Marı A Maneiro; Nafsika Forte; Maria M Shchepinova; Cyrille S Kounde; Vijay Chudasama; James Richard Baker; Edward W Tate
Journal:  ACS Chem Biol       Date:  2020-04-30       Impact factor: 5.100

Review 9.  Proteolysis targeting chimeras (PROTACs) in cancer therapy.

Authors:  Alberto Ocaña; Atanasio Pandiella
Journal:  J Exp Clin Cancer Res       Date:  2020-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.